Sertraline (Zoloft) Metabolism: Primary CYP450 Enzymes
Sertraline is metabolized by multiple CYP450 enzymes, with CYP2B6, CYP2C19, CYP2C9, CYP2D6, and CYP3A4 all contributing to its N-demethylation, though no single enzyme accounts for more than approximately 35-40% of total metabolism. 1, 2
Primary Metabolic Pathways
Sertraline undergoes extensive hepatic metabolism primarily through N-demethylation to form desmethylsertraline (its major metabolite). The metabolic profile involves:
Main Contributing Enzymes (in order of contribution):
- CYP2B6: Contributes approximately 35% of N-demethylation activity 1
- CYP2D6: Accounts for approximately 35% 1
- CYP2C9: Contributes approximately 29% 1
- CYP2C19: Accounts for approximately 13-14% 1
- CYP3A4: Contributes approximately 9% 1
However, more recent research suggests CYP2B6 may be the greatest contributor to sertraline metabolism 2, with CYP2C19 playing a particularly important role in the high-affinity (low concentration) metabolic pathway 3.
Clinical Significance of Genetic Polymorphisms
CYP2C19 Polymorphisms
CYP2C19 genetic variation has the most clinically relevant impact on sertraline pharmacokinetics 4, 5:
- Poor metabolizers (PMs) show significantly reduced metabolic function, longer half-life, and reduced clearance compared to extensive metabolizers 4
- CYP2C19*17 carriers (increased activity) demonstrate decreased AUC and half-life 5
- CYP2C19 catalyzes the high-affinity N-demethylation pathway 3
CYP2B6 Polymorphisms
CYP2B6 genetic variants also influence sertraline exposure 5:
- Individuals with CYP2B6 G516T T/T genotype show higher AUC and half-life
- Anti-CYP2B6 antibodies inhibit sertraline N-demethylation by approximately 35% 1
CYP2D6 Polymorphisms
Despite CYP2D6's contribution to metabolism, genetic polymorphisms in CYP2D6 show limited or inconsistent effects on sertraline pharmacokinetics in clinical settings 6. The FDA label notes that sertraline has "a less prominent inhibitory effect on 2D6 than some others in the class" 7.
Important Clinical Caveats
Why Multiple Enzyme Involvement Matters
The involvement of multiple CYP450 enzymes provides a safety buffer: No single drug interaction or genetic polymorphism is likely to cause marked increases in sertraline plasma concentrations 1, 2. This is a critical advantage over SSRIs metabolized predominantly by a single enzyme.
Additional Metabolic Pathways
Beyond CYP450 enzymes:
- Monoamine oxidases A and B catalyze sertraline deamination 2
- UGT2B7 (glucuronyl transferase) catalyzes N-carbamoyl glucuronidation 2
Drug Interaction Profile
The FDA label confirms sertraline:
- Inhibits CYP2D6 (though less than other SSRIs) 7
- Has minimal effect on CYP3A4 (may actually induce it slightly) 7
- Shows time-dependent inhibition of CYP3A4 through metabolic intermediate complex formation 8
Pharmacogenetic Testing Considerations
Current CPIC guidelines consider both CYP2B6 and CYP2C19 actionable for sertraline dosing 9. The 2016 Mayo Clinic guideline provides a framework for interpreting CYP2D6 and CYP2C19 metabolizer phenotypes 10, though evidence for routine testing remains limited 4.
When accounting for concomitant medications that modify enzyme activity (phenoconversion), CYP2B6 and CYP2C19 phenotypes show more consistent patterns with sertraline exposure variability 6. This suggests that integrating medication history with genetic testing may improve clinical utility.